We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+9.46%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.97B
AUM Growth
+$53.8M
Cap. Flow
-$151M
Cap. Flow %
-5.09%
Top 10 Hldgs %
47.74%
Holding
40
New
8
Increased
11
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$117M
2
CAH icon
Cardinal Health
CAH
+$73M
3
SKIN icon
SkinHealth Systems
SKIN
+$54.7M
4
HOLX
Hologic
HOLX
+$44.5M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$44.2M

Top Sells

Rank Stock Value
1
CHNG
Change Healthcare Inc. Common Stock
CHNG
+$205M
2
ZBH icon
Zimmer Biomet
ZBH
+$100M
3
UHS icon
Universal Health Services
UHS
+$94.5M
4
WELL icon
Welltower
WELL
+$58M
5
VTR icon
Ventas
VTR
+$48M

Sector Composition

Rank Sector Weight
1 Healthcare 80.75%
2 Consumer Staples 2.26%
3 Technology 1.82%
4 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THC icon
1
Tenet Healthcare
THC
$21.8B
$191M 6.43%
2,850,000
-150,000
-5% -$9.3M
WBA
2
DELISTED
Walgreens Boots Alliance
WBA
$184M 6.2%
3,500,000
-250,000
-7% -$13.4M
VTRS icon
3
Viatris
VTRS
$20.7B
$171M 5.78%
12,000,000
– –
MRK icon
4
CALL
Merck
MRK
$321B
$156M 5.24%
+2,000,000
New +$149M
HCA icon
5
HCA Healthcare
HCA
$85.7B
$124M 4.18%
600,000
-175,000
-23% -$35.7M
BKD icon
6
Brookdale Senior Living
BKD
$3.49B
$121M 4.09%
15,350,000
+2,850,000
+23% +$20.5M
AZN icon
7
CALL
AstraZeneca
AZN
$266B
$120M 4.04%
+1,000,000
New +$110M
SNY icon
8
Sanofi
SNY
$103B
$118M 3.99%
+2,250,000
New +$117M
MRK icon
9
Merck
MRK
$321B
$117M 3.93%
1,500,000
+452,000
+43% +$33.6M
PRGO icon
10
Perrigo
PRGO
$1.43B
$115M 3.86%
2,500,000
-300,000
-11% -$13.3M
UHS icon
11
Universal Health Services
UHS
$9.88B
$113M 3.82%
775,000
-625,000
-45% -$94.5M
GSK icon
12
GSK
GSK
$104B
$110M 3.69%
2,200,000
+200,000
+10% +$9.61M
ALKS icon
13
Alkermes
ALKS
$8.39B
$105M 3.55%
4,300,000
-1,300,000
-23% -$28.9M
IRWD icon
14
Ironwood Pharmaceuticals
IRWD
$614M
$96.5M 3.25%
7,500,000
– –
GILD icon
15
Gilead Sciences
GILD
$163B
$96.4M 3.25%
1,400,000
+400,000
+40% +$26.7M
MYGN icon
16
Myriad Genetics
MYGN
$507M
$91.7M 3.09%
3,000,000
– –
IONS icon
17
Ionis Pharmaceuticals
IONS
$8.81B
$79.8M 2.69%
2,000,000
+1,000,000
+100% +$39.2M
PFE icon
18
CALL
Pfizer
PFE
$142B
$78.3M 2.64%
+2,000,000
New +$77.8M
CAH icon
19
Cardinal Health
CAH
$53.2B
$71.4M 2.4%
+1,250,000
New +$73M
GILD icon
20
CALL
Gilead Sciences
GILD
$163B
$68.9M 2.32%
+1,000,000
New +$66.8M
SKIN icon
21
SkinHealth Systems
SKIN
$87.6M
$67.2M 2.26%
+4,000,000
New +$54.7M
RETA
22
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$65.8M 2.22%
465,000
+65,000
+16% +$7.34M
MRTX
23
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$64.6M 2.18%
400,000
+275,000
+220% +$44.2M
NKTR icon
24
Nektar Therapeutics
NKTR
$2.41B
$60.1M 2.02%
233,333
+100,000
+75% +$27.7M
TEVA icon
25
Teva Pharmaceuticals
TEVA
$41.2B
$54.5M 1.83%
5,500,000
– –
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Camber Capital Management held 40 positions worth $2.97B, up 1.8% from $2.91B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Camber Capital Management withdrew a net $151M in Q2 2021, closing 6 positions and reducing 7 holdings. Its most notable exit was Zimmer Biomet, an estimated $100M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 73% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Camber Capital Management opened a new position in Sanofi worth $118M.

  • Camber Capital Management's largest Q2 2021 buy was Sanofi: 2,250,000 shares worth $118M.
  • Camber Capital Management added most to Mirati Therapeutics, Inc. Common Stock in Q2 2021, an estimated $44.2M increase.
  • Camber Capital Management's biggest Q2 2021 reduction was Change Healthcare Inc. Common Stock, cutting an estimated $205M.
  • Camber Capital Management fully exited Zimmer Biomet in Q2 2021, selling an estimated $100M.
  • Camber Capital Management's ten largest holdings make up 48% of its $2.97B portfolio in Q2 2021.
  • Camber Capital Management opened 8 new positions and closed 6 in Q2 2021.
  • Camber Capital Management's portfolio value rose 1.8% quarter-over-quarter to $2.97B.

Based on Camber Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.